Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT

NESS ZIONA, Israel—(BUSINESS WIRE)—Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, production and marketing of specialty life-saving biotherapeutics, announced today that it has completed patient enrollment in its Phase II clinical trial evaluating treatment of bronchiectasis patients with inhaled Alpha-1 Antitrypsin (AAT) delivered by the investigational eFlow® nebulizer system (PARI Pharma GmbH).

To read full press release, click here.